322 Federal Register / Vol. 60, No. 2 / Wednesday, January 4, 1995 / Rules and Regulations

Federal Assistance Program

The title and number of the Federal

Assistance Program, as found in the

Catalog of Federal Domestic Assistance,

to which this rule applies are

Commodity Loans and Purchases—

10.051.

Regulatory Flexibility Act

It has been determined that the

Regulatory Flexibility Act is not

applicable because the CCC is not

required by 5 U.S.C. 553 or any other

provision of law to publish a notice of

proposed rulemaking with respect to the

subject matter of these determinations.

Environmental Evaluation

It has been determined by an

environmental evaluation that this

action will have no significant impact

on the quality of human environment.

Executive Order 12372

This program is not subject to the

provisions of Executive Order 12372,

which requires intergovernmental

consultation with State and local

officials. See the Notice related to 7 CFR

part 3015, subpart V, published at 48 FR

29115 (June 24, 1983).

Executive Order 12778

This final rule has been reviewed

pursuant to Executive Order 12788. To

the extent State and local laws are in

conflict with these regulatory

provisions, it is the intent of CCC that

the terms of the regulations prevail. The

provisions of this final rule are not

retroactive. Prior to any judicial action

in a court of competent jurisdiction,

administrative review under 7 CFR part

780 must be exhausted.

Paperwork Reduction Act

Public reporting burden for the

information collections contained in

this regulation with respect to price

support programs is estimated to

average 15 minutes per response,

including time for reviewing

instructions, searching existing data

sources, gathering and maintaining the

data needed, and completing and

reviewing the collections of

information. The information

collections have previously been cleared

under the current regulations by OMB,

and assigned OMB Nos. 0560–0087 and

0560–0129.

Interim Rule

The interim rule published in the

Federal Register on May 9, 1994, with

respect to the Honey Price Support Loan

Program amended the price support

loan rates for 1994 through 1998;

revised the limitation on the total

amount of payments a producer may

receive; revised the provisions of the

honey marketing assessment; lessened

the administrative actions Commodity

Credit Corporation (CCC) imposes on

producers who violate the loan and loan

deficiency payment agreements;

provided more authority to State and

county CFSA committees in

administering the program; eliminated

obsolete provisions, and incorporated

the provisions of the Agriculture, Rural

Development, Food and Drug

Administration, and Related Agencies

Appropriations Act, 1994, and the

Omnibus Budget Reconciliation Act of

1993.

Comments

No comments were received during

the comment period which ended on

June 8, 1994.

Accordingly, the interim rule

published at 59 FR 23789 on May 9,

1994, which amended 7 CFR part 1434

is hereby adopted as a final rule without

change.

Signed in Washington, DC, on December

27, 1994.

Bruce R. Weber,

Acting Executive Vice President, Commodity

Credit Corporation.

[FR Doc. 95–00133 Filed 1–3–95; 8:45 am]

BILLING CODE 3410–05–P–M

NUCLEAR REGULATORY

COMMISSION

10 CFR Part 32

RIN: 3150–AD69

Preparation, Transfer for Commercial

Distribution, and Use of Byproduct

Material for Medical Use

AGENCY: Nuclear Regulatory

Commission.

ACTION: Final rule; clarification.

SUMMARY: The Nuclear Regulatory

Commission (NRC) is amending

regulatory text and the response to a

public comment contained in a final

rule published in the Federal Register

on Friday, December 2, 1994, entitled

‘‘Preparation, Transfer for Commercial

Distribution, and Use of Byproduct

Material for Medical Use.’’ This action

is necessary following reconsideration

by the NRC regarding the requirements

for the information to be included on

labels for radioactive drugs to be

transferred for commercial distribution.

The effect of this action is to reduce

regulatory burden and uncertainty for

licensees that manufacture and

distribute radiopharmaceuticals that

contain byproduct material for medical

use.

EFFECTIVE DATE: January 1, 1995.

ADDRESSES: Copies of the public record,

including the final regulatory analysis

and any public comments received on

the proposed rule, may be examined

and copied for a fee in the

Commission’s Public Document Room

at 2120 L Street, NW. (Lower Level),

Washington, DC.

FOR FURTHER INFORMATION CONTACT: Mr.

John L. Telford (301) 415–6229 or Mr.

Samuel Z. Jones (301) 415–6198, Office

of Nuclear Regulatory Research, U.S.

Nuclear Regulatory Commission,

Washington, DC 20555.

SUPPLEMENTARY INFORMATION:

I. Background

On Friday, December 2, 1994 (59 FR

61767), the NRC published in the

Federal Register a final rule regarding

10 CFR Parts 30, 32, and 35

(Preparation, Transfer for Commercial

Distribution, and the Use of Byproduct

Material for Medical Use). On Thursday,

November 17, 1994, the NRC staff

received comments on the regulatory

guides associated with this rulemaking

action during a public meeting with the

NRC’s Advisory Committee on the

Medical Uses of Isotopes (ACMUI).

Initially, the NRC staff believed that

these comments could be resolved

through appropriate regulatory

guidance. However, these comments

resulted in the NRC staff concluding

that the final published requirements in

10 CFR 32.72(a)(4)

(1) Contained an undue burden with

regard to the information required to be

included on syringe labels; and

(2) Were not clear with regard to what

was meant by a ‘‘container.’’

The NRC staff subsequently

developed revised regulations to specify

the information to be included on each

label. In this rulemaking, the NRC is

modifying the requirements of 10 CFR

32.72(a)(4) before the published

effective date of January 1, 1995. This

rulemaking will minimize intrusion into

areas related to the practice of medicine

in a manner consistent with the

Commission’s policy as published on

February 9, 1979 (44 FR 8242), entitled

‘‘Regulation of the Medical Uses of

Radioisotopes; Statement of General

Policy’’ and minimize the regulatory

burden on licensees. The specific

revised requirements and response to

the public comment are provided in this

document.
Federal Register / Vol. 60, No. 2 / Wednesday, January 4, 1995 / Rules and Regulations 323

II. Discussion

A. Revised NRC Response to the Public

Comment

The following comment, in regard to

10 CFR 32.72(a)(4), was published in the

Federal Register on Friday, December 2,

1994 (59 FR 61771):

‘‘(3) Comment. The syringe label

should not be limited to the clinical

procedure. On the other hand, it is

unnecessary to require that the label, or

the leaflet or brochure that accompanies

the radioactive drug, contain all of the

statements specified in the proposed

rule.’’

The Commission agrees with the

comment regarding syringe labels. The

revised response is:

On page 61771, in the first column,

the second complete paragraph and the

first sentence of the third complete

paragraph are withdrawn and replaced

by the following text:

Response. (a) The revised regulations

in § 32.72(a)(4)(ii) require that labels for

syringes, vials, or other containers used

to hold radioactive drugs to be

transferred for commercial distribution

must include the radiation symbol and

the words ‘‘CAUTION, RADIOACTIVE

MATERIAL’’ or ‘‘DANGER,

RADIOACTIVE MATERIAL’’ and an

identifier that ensures that the syringe,

vial, or other container can be correlated

with the information on the transport

radiation shield label. The radiation

symbol has been included for the

protection of public health and safety.

In the event that a syringe, vial, or other

container becomes separated from its

transport radiation shield, it would be

readily identifiable as radioactive. The

radiation symbol is currently required

by § 20.1904 to be on containers of

radioactive material and that

requirement is restated in § 32.72 as a

matter of convenience for licensees.

This radiation symbol will also need to

be the same as described in § 20.1901.

The identifier has been included to

provide a correlation between a syringe,

vial, or other container and the

information on the label of its transport

radiation shield. The benefits of this

correlation are: the transport radiation

shield label provides more information

than the syringe, vial, or other container

label; it allows confirmation that the

syringe, vial, or other container is in the

correct transport radiation shield; and

this additional information facilitates

the radioactive drug being administered

as directed by a physician authorized

user. Thus, this correlation is necessary

for both radiation safety and patient

safety. By not specifying the identifier,

the NRC staff has provided maximum

flexibility for licensees to select the

identifier that best suits their

operations. Acceptable identifiers may

include prescription number, name of

the radioactive drug or its abbreviation,

the patient’s name, or the clinical

procedure.

The revised regulations do not require

‘‘the clinical procedure to be performed

or the patient’s or the human research

subject’s name’’ to be included on the

syringe label since this information may

or may not be available to commercial

nuclear pharmacies. However, this

regulation does not preclude other

information from being included on the

syringe label, such as the clinical

procedure when this information is

available and appropriate. Also, the

phrase ‘‘syringe radiation shield’’ has

been deleted to eliminate any confusion

between this shield and the transport

radiation shield. The phrases ‘‘vial’’ and

‘‘other container’’ have been added to

make clear that the regulatory

requirements of § 32.72(a)(4)(ii) are not

limited to syringes but apply to any

container used to hold a radioactive

drug to be transferred for commercial

distribution, e.g., generator or ampule.

In addition to these modifications, the

revised regulations in § 32.72(a)(4)(i)

replace the word ‘‘container’’ with the

phrase ‘‘transport radiation shield’’ to

make clear the placement of the label

containing the specified information.

The transport radiation shield could be

constructed of lead, glass, plastic, or

other material as is appropriate for the

isotope to be transferred for commercial

distribution. However, the phrase

‘‘transport radiation shield’’ does not

refer to the outer suitcase, package,

packing, or other carrying device, even

though that barrier may provide some

radiation shielding. Also, there are two

modifications to the information to be

included on this label. First, this label

must now include the radiation symbol

and the words ‘‘CAUTION,

RADIOACTIVE MATERIAL’’ or

‘‘DANGER, RADIOACTIVE

MATERIAL.’’ The radiation symbol has

been included for the protection of

public health and safety so that this

item can be readily identified as

radioactive. Second, the phrase ‘‘date

and time of assay’’ has been replaced

with ‘‘at a specified date and time.’’

This new phrase recognizes the current

licensee practice of providing a date and

time on this label that is the specified

date and time at which the syringe, vial,

or other container will hold the stated

quantity of radioactivity rather than the

actual date and time of assay. In

addition, if a syringe, vial, or other

container does not require a ‘‘transport

radiation shield’’ because the syringe,

vial, or other container itself provides

sufficient radiation shielding, then the

information on the label of the syringe,

vial, or other container must include the

items specified in § 32.72(a)(4)(i).

Furthermore, complying with these NRC

labeling requirements does not relieve

licensees from complying with other

applicable requirements (e.g., U.S.

Department of Transportation) for

labeling the outer suitcase or package.

(b) The Commission agrees with the

comment that it is unnecessary to

require that the label, or the leaflet or

brochure that accompanies the

radioactive drug, contain all of the

statements specified in the proposed

rule. Therefore, the Commission is

deleting the sentence in § 32.72(a)(4)

reading: ‘‘Furthermore, the label, or the

leaflet or brochure that accompanies the

radioactive drug, must contain a

statement that the U.S. Nuclear

Regulatory Commission has approved

distribution of the byproduct material to

persons licensed to use byproduct

material pursuant to 10 CFR 35.100,

35.200, or 35.300, as appropriate, and to

persons who hold an equivalent license

issued by an Agreement State.’’ This

sentence was deleted because as

revised, the regulations provide greater

flexibility and responsibility for

licensees. The licensees distributing

radioactive drugs must confirm that the

recipients are licensed to receive the

radioactive drugs and the medical use

recipients who can compound

radioactive drugs are responsible for

ensuring the appropriate uses of those

radioactive drugs. Thus, licensees will

need to continue to ensure pursuant to

§ 30.41(c) that radioactive drugs are only

distributed to persons authorized to

receive such byproduct materials. The

Commission is removing from the text

of the rule the last sentence of

§ 32.72(a)(4) reading: ‘‘The

Commission’s labeling requirements are

independent of requirements of the U.S.

Food and Drug Administration (FDA);

one label is acceptable to NRC provided

that it contains all of the information

which NRC requires.’’ This sentence is

being placed in the preamble because

this statement is not a regulatory

requirement and simply provides

factual information.

B. Justification

These modifications relieve a

restriction and result in a relaxation of

the labeling requirements and are

exempt from the requirements for a 30-

day delay in the effective date under 5

U.S.C. 553(d)(1). Therefore, this

modification is being made effective on

January 1, 1995, to coincide with the

effective date for the remainder of the

previously published final rule. Further,
324 Federal Register / Vol. 60, No. 2 / Wednesday, January 4, 1995 / Rules and Regulations

as provided in 5 U.S.C. 553(d)(3), good

cause exists for making the modification

effective on less than 30 days notice. As

originally written, the rule would have

required that information be included

on syringe labels that might not be

available to the commercial nuclear

pharmacy. This would have made

compliance difficult or impossible in

some instances. Failure to make this

modification effective on the same date

as the originally published final rule

would run the risk of either disrupting

the availability of radiopharmaceuticals,

if nuclear pharmacies refused to ship

materials without the information

needed under the originally published

final rule, or shipments being made in

violation of the rule because of a

medical need for the radioactive drugs

but a lack of needed information at the

nuclear pharmacy facility. Thus, even if

this change did not involve a relaxation

of a regulatory requirement, meeting the

criteria of 5 U.S.C. 553(d)(1) for

exception from the 30-day notice

requirement, the Commission finds the

January 1, 1995, effective date justified

under the ‘‘good cause’’ exception in 5

U.S.C. 553(d)(3).

III. Administrative Statements

Finding of No Significant

Environmental Impact: Availability

The Commission has determined

under the National Environmental

Policy Act of 1969, as amended, and the

Commission’s regulations in Subpart A

of 10 CFR Part 51, that this final

amendment is not a major Federal

action significantly affecting the quality

of the human environment, and

therefore an environmental impact

statement is not required. This final

amendment clarifies the NRC’s intent

regarding the information to be included

on labels for radioactive drugs to be

transferred for commercial distribution.

It is expected that there will be no

increase in radiation exposure to the

public or to the environment beyond the

exposures currently resulting from

transporting radioactive drugs. The NRC

prepared an environmental assessment

and finding of no significant impact for

the final rule published December 2,

1994 (59 FR 61767), and it is available

for inspection at the NRC Public

Document Room, 2120 L Street, NW.

(Lower Level), Washington, DC. This

rulemaking action does not make any

substantive changes that would affect

the conclusions reached in that

assessment. Single copies of the

environmental assessment and finding

of no significant impact are available

from John L. Telford or Samuel Z. Jones

(see FOR FURTHER INFORMATION CONTACT

heading).

Paperwork Reduction Act Statement

This rulemaking action amends

information collection requirements that

are subject to the Paperwork Reduction

Act of 1980 (44 U.S.C. 3501 et seq).

These requirements were approved by

the Office of Management and Budget,

approval number 3150–0001 for

amendments to 10 CFR Parts 32.

The public burden for this collection

of information is estimated to be no

change from the current requirements,

including the time for reviewing

instructions, searching existing data

sources, gathering and maintaining the

data needed, and completing and

reviewing the collection of information.

Send comments regarding this burden

estimate or any other aspect of this

collection of information, including

suggestions for reducing this burden, to

the Information and Records

Management Branch (T–6 F33), U.S.

Nuclear Regulatory Commission,

Washington, DC 20555, and to the Desk

Officer, Office of Information and

Regulatory Affairs, NEOB–10202,

(3150–0001, –0010, and –0120), Office

of Management and Budget,

Washington, DC 20503.

Regulatory Analysis

The Commission prepared a

regulatory analysis for the final rule

published December 2, 1994 (59 FR

61767). This rulemaking action does not

make any substantive changes that

would change the conclusions reached

in that analysis. The regulatory analysis

is available for inspection at the NRC

Public Document Room at 2120 L Street,

NW. (Lower Level), Washington, DC.

Single copies of the regulatory analysis

are available from John L. Telford or

Samuel Z. Jones (see FOR FURTHER

INFORMATION CONTACT heading).

Regulatory Flexibility Certification

As required by the Regulatory

Flexibility Act of 1980, 5 U.S.C. 605(b),

the Commission certifies that this rule

will not have a significant economic

impact on a substantial number of small

entities. This rule affects manufacturers

and commercial nuclear pharmacies.

These licensees would not be

considered small entities under the

NRC’s size standards (56 FR 56671;

November 6, 1991). This rulemaking

action clarifies the NRC’s intent

regarding the information to be included

on labels for radioactive drugs to be

transferred for commercial distribution

and is expected to result in no change

of burden for the affected licensees.

Backfit Analysis

The Commission has determined that

the backfit rule, 10 CFR 50.109, does not

apply to this amendment because this

amendment does not involve any

provisions which would impose backfits

as defined in 10 CFR 50.109(a)(1).

Therefore, a backfit analysis is not

required for this amendment.

List of Subjects in 10 CFR Part 32

Byproduct material, Criminal

penalties, Labeling, Nuclear materials,

Radiation protection, Reporting and

recordkeeping requirements.

For the reasons set out in the

preamble and under the authority of the

Atomic Energy Act of 1954, as amended,

the Energy Reorganization Act of 1974,

as amended, and 5 U.S.C. 552 and 553,

the NRC is adopting the following

amendments to 10 CFR Part 32.

PART 32—SPECIFIC DOMESTIC

LICENSES TO MANUFACTURE OR

TRANSFER CERTAIN ITEMS

CONTAINING BYPRODUCT MATERIAL

1. The authority citation for Part 32

continues to read as follows:

Authority: Secs. 81, 161, 182, 183, 68 Stat.

935, 948, 953, 954, as amended (42 U.S.C.

2111, 2201, 2232, 2233); sec. 201, 88 Stat.

1242, as amended (42 U.S.C. 5841).

2. In § 32.72 paragraph (a)(4) is

revised to read as follows:

§ 32.72 Manufacture, preparation, or

transfer for commercial distribution of

radioactive drugs containing byproduct

material for medical use under Part 35.

(a) * * *

(4) The applicant satisfies the

following labeling requirements:

(i) A label is affixed to each transport

radiation shield, whether it is

constructed of lead, glass, plastic, or

other material, of a radioactive drug to

be transferred for commercial

distribution. The label must include the

radiation symbol and the words

‘‘CAUTION, RADIOACTIVE

MATERIAL’’ or ‘‘DANGER,

RADIOACTIVE MATERIAL’’; the name

of the radioactive drug or its

abbreviation; and the quantity of

radioactivity at a specified date and

time. For radioactive drugs with a half

life greater than 100 days, the time may

be omitted.

(ii) A label is affixed to each syringe,

vial, or other container used to hold a

radioactive drug to be transferred for

commercial distribution. The label must

include the radiation symbol and the

words ‘‘CAUTION, RADIOACTIVE

MATERIAL’’ or ‘‘DANGER,

RADIOACTIVE MATERIAL’’ and an

identifier that ensures that the syringe,
Federal Register / Vol. 60, No. 2 / Wednesday, January 4, 1995 / Rules and Regulations 325

vial, or other container can be correlated

with the information on the transport

radiation shield label.

* * * * *

Dated at Rockville, Maryland, this 28th day

of December, 1994.

For the Nuclear Regulatory Commission.

Hugh L. Thompson, Jr.,

Acting Executive Director for Operations.

[FR Doc. 95–00124 Filed 1–3–95; 8:45 am]

BILLING CODE 7590–01–P

FARM CREDIT ADMINISTRATION

12 CFR Parts 607, 614, 615, and 620

RIN 3052–AB44

Assessment and Apportionment of

Administrative Expenses; Loan

Policies and Operations; Funding and

Fiscal Affairs, Loan Policies and

Operations, and Funding Operations;

Disclosure to Shareholders; Effective

Date

AGENCY: Farm Credit Administration.

ACTION: Notice of effective date.

SUMMARY: The Farm Credit

Administration (FCA) published a final

regulation under parts 607, 614, 615,

and 620 on July 22, 1994 (59 FR 37400).

The final regulation amends 12 CFR

parts 607, 614, 615, and 620 to establish

requirements for the agreement between

a Farm Credit Bank (FCB) and its related

direct lender associations specifying

where the earnings held by the FCB and

allocated to associations may be

counted as permanent capital, to specify

how there earnings would be counted in

the absence of an agreement, to provide

a date certain for the exclusion from

capital of payments by Farm Credit

institutions to the Farm Credit System

Financial Assistance Corporation made

in connection with the repayment of

Treasury-paid interest, and to make

other conforming changes to implement

the statutory amendments. Technical

and conforming changes are made

throughout the agency’s regulations. In

accordance with 12 U.S.C. 2252, the

effective date of the final rule is 30 days

from the date of publication in the

Federal Register during which either or

both Houses of Congress are in session.

Based on the records of the sessions of

Congress, the effective date of the

regulations is December 31, 1994.

EFFECTIVE DATE: The regulation

amending 12 CFR parts 607, 614, 615,

and 620 published on July 22, 1994 (59

FR 37400) is effective December 31,

1994.

FOR FURTHER INFORMATION CONTACT:

Robert S. Child, Policy Analyst,

Regulation Development, Office of

Examination, Farm Credit

Administration, McLean, Virginia

22102–5090, (703) 883–4498, TDD

(703) 883–4444, or

Rebecca S. Orlich, Senior Attorney,

Office of General Counsel, Farm

Credit Administration, McLean,

Virginia 22102–5090, (703) 883–4020,

TDD (703) 883–4444.

(12 U.S.C. 2252(a)(9) and (10))

Dated: December 29, 1994.

Floyd Fithian,

Acting Secretary, Farm Credit Administration

Board.

[FR Doc. 95–131 Filed 1–3–95; 8:45 am]

BILLING CODE 6705–01–P

12 CFR Part 612

RIN 3052–AB47

Personnel Administration; Effective

Date

AGENCY: Farm Credit Administration.

ACTION: Notice of effective date.

SUMMARY: The Farm Credit

Administration (FCA) published a final

regulation under part 612 on May 13,

1994 (59 FR 24889). The final regulation

amends 12 CFR part 612 to reflect

statutory changes and the change in

focus of the FCA’s regulatory oversight

of personnel matters. In addition, the

final rule enhances and clarifies the

regulations to ensure that they fulfill the

purposes of section 514 of the Farm

Credit Banks and Associations Safety

and Soundness Act of 1992 relative to

the reporting of financial information

and potential conflicts of interest. In

accordance with 12 U.S.C. 2252, the

effective date of the final rule is 30 days

from the date of publication in the

Federal Register during which either or

both Houses of Congress are in session.

Based on the records of the sessions of

Congress, the effective date of the

regulations is December 31, 1994.

EFFECTIVE DATE: The regulation

amending 12 CFR part 612 published on

May 13, 1994 (59 FR 24889) is effective

December 31, 1994.

FOR FURTHER INFORMATION CONTACT:

John J. Hays, Policy Analyst, Policy

Development and Planning Division,

Office of Examination, Farm Credit

Administration, McLean, Virginia

22102–5090, (703) 883–4498, TDD

(703) 883–4444, or

Dorothy J. Acosta, Assistant General

Counsel, Regulatory Operations

Division, Office of General Counsel,

Farm Credit Administration, McLean,

Virginia 22102–5090, (703) 883–4020,

TDD (703) 883–4444.

(12 U.S.C. 2252(a)(9) and (10))

Dated: December 29, 1994.

Floyd Fithian,

Acting Secretary, Farm Credit Administration

Board.

[FR Doc. 95–130 Filed 1–3–95; 8:45 am]

BILLING CODE 6705–01–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 25

[Docket No. NM–104; Special Conditions

No. 25–ANM–93]

Special Conditions: Modified Cessna

550 Series Airplanes, High Intensity

Radiated Fields (HIRF)

AGENCY: Federal Aviation

Administration, DOT.

ACTION: Final special conditions with

request for comments.

SUMMARY: These special conditions are

issued for the Cessna 550 series

airplanes modified by Modern Avionics,

Inc., of Eden Praire, Minnesota. These

airplanes are equipped with digital

electronic flight instrument systems

(EFIS) that perform critical functions.

The applicable type certification

regulations do not contain adequate or

appropriate safety standards for the

protection of these systems from the

effects of high intensity radiated fields

(HIRF). These special conditions

provide the additional safety standards

that the Administrator considers

necessary to ensure that the critical

functions that these systems perform are

maintained when the airplane is

exposed to HIRF.

DATES: The effective date of these

special conditions is December 20,

1994. Comments must be received on or

before February 21, 1995.

ADDRESSES: Comments on these special

conditions may be mailed in triplicate

to: Federal Aviation Administration,

Transport Airplane Directorate (ANM–

100), Attn: Docket No. NM–104, 1601

Lind Avenue SW, Renton, WA 98055–

4056; or delivered in triplicate to the

Transport Airplane Directorate at the

above address. Comments must be

marked; Docket No. NM–104.

Comments may be inspected weekdays,

except Federal holidays, between 7:30

a.m. and 4:00 p.m.

FOR FURTHER INFORMATION CONTACT:

Michael Zielinski, FAA,

Standardization Branch, ANM–113,

Transport Airplane Directorate, Aircraft